TABLE 3:
Comparison of Daily Frequency of Bowel Movements, Treatment Modalities, Endoscopic Features, and Clinical Outcomes Among Non-ICPI-Induced MC in Cancer Patients, ICPI-Induced MC in Cancer Patients, and Traditional MC in Noncancer Patients
| Characteristic | No. Patients (%) | P | ||
|---|---|---|---|---|
| Non-ICPI-Induced MC With Cancer | ICPI-Induced MC With Cancer | Traditional MC Without Cancer | ||
| n = 39 | n = 15 | n = 11 | ||
| Daily frequency of bowel movements | 0.185 | |||
| ≤6 | 23 (59) | 5 (33) | 7 (64) | |
| >6 | 16 (41) | 10 (67) | 4 (36) | |
| Colitis treatments | 0.035 | |||
| Yes | 25 (64) | 14 (93) | 10 (91) | |
| No | 14 (36) | 1 (7) | 1 (9) | |
| Colitis treatmentsa | ||||
| Antidiarrheals | 5 (20) | 7 (50) | 1 (10) | 0.052 |
| Aminosalicylates | 4 (16) | 4 (27) | 4 (40) | 0.310 |
| Budesonide | 21 (84) | 6 (43) | 9 (90) | 0.008 |
| Other oral steroids | 0 (0) | 12 (86) | 1 (10) | <0.001 |
| Intravenous steroids | 0 (0) | 5 (36) | 0 (0) | <0.001 |
| Infliximab/vedolizumab | 1 (4) | 8 (57) | 0 (0) | <0.001 |
| Endoscopic featuresb | 0.106 | |||
| Mucosal abnormality | 5 (13) | 7 (47) | 3 (27) | |
| Tubular adenoma | 6 (15) | 4 (27) | 0 (0) | |
| Both | 2 (5) | 0 (0) | 1 (9) | |
| Normal | 25 (64) | 4 (27) | 7 (64) | |
| Clinical outcomes | ||||
| Recurrence | 12 (31) | 6 (40) | 5 (46) | 0.502 |
| Hospitalization | 0 (0) | 6 (40) | 0 (0) | <0.001 |
| Death | 0 (0) | 2 (13) | 0 (0) | 0.032 |
aSome patients required multiple colitis treatments. Percentages are out of the number treated.
bEndoscopic features are available for 38 of 39 non-ICPI-induced MC cancer patients.